Revilico

Revilico is a pre-clinical stage biotechnology company focused on developing novel therapies at the intersection of metabolism and inflammation. The company leverages a proprietary platform to identify endogenous metabolites that act as natural regulators of the immune system, aiming to treat chronic inflammatory and autoimmune conditions. By harnessing these metabolic pathways, Revilico seeks to create highly specific small molecule drugs with improved safety profiles compared to traditional immunosuppressants. The firm was founded by industry veterans and academic experts from Brigham and Women's Hospital. Revilico is backed by leading life science investors, including Atlas Venture, to advance its pipeline of metabolic-based immunotherapies.